4D Molecular Therapeutics
Total Raised
$183.59MInvestors Count
20Deal Terms
3Funding, Valuation & Revenue
7 Fundings
4D Molecular Therapeutics has raised $183.59M over 7 rounds.
4D Molecular Therapeutics's latest funding round was a IPO for $193.2M on December 11, 2020.
4D Molecular Therapeutics's latest post-money valuation is from December 2020.
Sign up for a free demo to see 4D Molecular Therapeutics's valuations in December 2020 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
12/11/2020 | IPO | $193.2M | 4 | |||
6/16/2020 | Series C | $13.61M (25.13x) FY 2020 | ||||
9/5/2018 | Series B | |||||
10/19/2015 | Series A - II | |||||
8/14/2015 | Series A |
Date | 12/11/2020 | 6/16/2020 | 9/5/2018 | 10/19/2015 | 8/14/2015 |
|---|---|---|---|---|---|
Round | IPO | Series C | Series B | Series A - II | Series A |
Amount | $193.2M | ||||
Investors | |||||
Valuation | |||||
Revenue | $13.61M (25.13x) FY 2020 | ||||
Sources | 4 |
4D Molecular Therapeutics Deal Terms
3 Deal Terms
4D Molecular Therapeutics's deal structure is available for 3 funding rounds, including their IPO from December 11, 2020.
Round | IPO | Series B | Series A |
|---|---|---|---|
Funding Date | |||
Pre-Money Valuation | |||
Post-Money Valuation | |||
Amount Raised | |||
Shares Authorized | |||
Issuance Price | |||
Dividend Rate | |||
Liquidation Preferences | |||
Liquidation Price | |||
Participation | |||
Conversion Price | |||
Anti Dilution | |||
General Voting | |||
Board Voting | |||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IPO | |||||||||||||||
Series B | |||||||||||||||
Series A |
4D Molecular Therapeutics Investors
20 Investors
4D Molecular Therapeutics has 20 investors. Pfizer Venture Investments invested in 4D Molecular Therapeutics's Series C funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
10/19/2015 | 6/16/2020 | 3 Series A - II, Series B (2018), Series C (2020) | Corporate Venture | New York | ||
9/5/2018 | 6/16/2020 | 2 Series B, Series C (2020) | Asset/Investment Management | New York | ||
9/5/2018 | 6/16/2020 | 2 Series B, Series C (2020) | Corporate Venture | Massachusetts | ||
Venture Capital | California | |||||
Hedge Fund | New York |
First funding | 10/19/2015 | 9/5/2018 | 9/5/2018 | ||
|---|---|---|---|---|---|
Last Funding | 6/16/2020 | 6/16/2020 | 6/16/2020 | ||
Investor | |||||
Rounds | 3 Series A - II, Series B (2018), Series C (2020) | 2 Series B, Series C (2020) | 2 Series B, Series C (2020) | ||
Board Seats | |||||
Type | Corporate Venture | Asset/Investment Management | Corporate Venture | Venture Capital | Hedge Fund |
Location | New York | New York | Massachusetts | California | New York |
Compare 4D Molecular Therapeutics to Competitors
Obsidian Therapeutics is involved in the development of engineered therapeutics within the biotechnology sector. The company creates precision medicines that utilize its cytoDRiVE platform to control the function of therapeutic proteins using FDA-approved small molecules. Obsidian Therapeutics operates within the healthcare sector, focusing on cell and gene therapies for patients with intractable diseases. It was founded in 2015 and is based in Cambridge, Massachusetts.
Arbor Biotechnologies operates as a gene editing company in the biotechnology sector, focusing on gene editing. The company specializes in the discovery and development of genomic medicines for patients with genetic diseases. Arbor Biotechnologies uses genomic editors to create targeted therapies for different diseases. It was founded in 2016 and is based in Cambridge, Massachusetts.
ReCode Therapeutics is a clinical-stage company that develops therapeutics for rare diseases within the biotechnology sector. The company utilizes its SORT lipid nanoparticle platform for the delivery of mRNA and gene correction therapies to various organs and tissues. ReCode Therapeutics serves the healthcare sector, specifically addressing rare and genetically defined diseases. It was founded in 2015 and is based in Menlo Park, California.
BioMarin focuses on developing and commercializing medicines for genetic conditions. The company offers treatments for life threatening conditions such as achondroplasia, severe hemophilia A, and various rare inherited and lysosomal storage diseases. BioMarin's pipeline comprises a range of investigational medicines at multiple stages of clinical and preclinical development. It was founded in 1997 and is based in San Rafael, California.
Pfizer operates as a biopharmaceutical company focused on the development of medicines and vaccines. It offers products for treating diseases and improving health outcomes, including therapies for internal medicine, inflammation and immunology, oncology, and vaccines. Its products are developed through research and clinical trials. Pfizer was formerly known as Charles Pfizer & Co. It was founded in 1849 and is based in New York, New York.
Merck operates as a biopharmaceutical company focused on developing medicines and vaccines. The company provides products for preventing and treating various diseases in humans and animals, including oncology, infectious diseases, cardio-metabolic disorders, immunology, neuroscience, and ophthalmology. Merck also utilizes data science and artificial intelligence in its therapeutic approaches. Merck was formerly known as Schering Plough. It was founded in 1891 and is based in Rahway, New Jersey.
Loading...